Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple Turns 50: From Garage Startup to AI Crossroads 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
NEW YORK, Sept. 06, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Middle District of Tennessee on behalf of investors who purchased Envision Healthcare Corporation ("Envision Healthcare") (NYSE:EVHC) securities between March 2, 2015 and July 21, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/envision-healthcare-corporation?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Envision Healthcare subsidiary EmCare Holdings, Inc. routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians; (ii) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians; (iii) the Company’s statements attributing EmCare’s Class Period growth to other factors were therefore false and/or misleading; (iv) Envision’s EmCare revenues were likely to be unsustainable after the foregoing conduct came to light; and (v) as a result of the foregoing, Envision’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Envision Healthcare you have until October 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/envision-healthcare-corporation?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
